Frenova

Frenova, founded in 2017, is a specialized clinical research services company that operates as a subsidiary of Fresenius Medical Care. Its core value proposition is accelerating renal disease clinical trials by providing sponsors with rapid access to a vast, pre-identified patient population across a global network of dialysis clinics and research sites. Beyond site management, Frenova monetizes its access to over 25 years of longitudinal data on more than two million kidney disease patients through analytics and data licensing, creating a unique, vertically integrated model in the nephrology research space. The company is positioned as a critical enabler for pharmaceutical and biotech companies developing treatments for chronic kidney disease (CKD) and end-stage renal disease (ESKD).

Integrated clinical trial acceleration platform leveraging a proprietary longitudinal nephrology database (>2M patients, 25+ years), technology-assisted patient screening, and a pre-activated site network (F1RST UP®) for rapid trial enrollment and execution.

Frenova competes with large, full-service global Contract Research Organizations (CROs) and other site management organizations (SMOs). Its key competitive advantage is non-replicable: direct, integrated access to Fresenius Medical Care's vast dialysis patient population and longitudinal data, which allows for dramatically faster patient identification and enrollment compared to traditional site networks.